Bryan Garnier - Novo Nordisk (novob) ... NOVO NORDISK - NEUTRAL | DKK330(+20%) Third-quarter figures very much in line with estimates

Report

Bryan Garnier

Eric Le Berrigaud

NOVO NORDISK - NEUTRAL | DKK330(+20%) Third-quarter figures very much in line with estimates

NOVO NORDISK - NEUTRAL | DKK330(+20%)
Third-quarter figures very much in line with estimates

Actual Q3 numbers are close to CS expectations
Restructuring costs weigh on operating expenses
Guidance is slightly narrowed
Recommendation is confirmed

01/11/2018 2 EN

Underlyings

Novo Nordisk

See profile

Novo Nordisk A/S Class B

Novo-Nordisk is a global healthcare company engaged in the innovation of diabetes care. Co. also provides haemophilia care, growth hormone therapy and hormone replacement therapy. The Diabetes care business segment includes research, development, manufacturing and marketing of products within the areas of insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD) and obesity. The Biopharmaceuticals business segment includes research, development, manufacturing and marketing of products within the areas of haemophilia, growth hormone therapy, hormone replacement therapy, inflammation therapy and other therapy areas.

See profile

DK0060534915 Nasdaq Nordic Copenhagen Denmark

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Eric Le Berrigaud

Other Reports on these Companies

SmartInsider

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS bought 2,350 shares at 349.044DKK and the significance rating of the trade was 61/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of bo...

Free Trial

August 19, 2025 August 19, 2025 1 EN

New Street Research

Novo - Upgrade to HOLD (PT DKK300, 8pgs)

With the orfo’ data being on the lower side of expectations, we upgrade to Hold as the narrative is likely to be dominated by the potential upside for Novo. However, we remain convinced that: 1) The obesity market is nowhere near as big as the market believes, 2) Ozempic no’s are far too high & 3) Margin forecasts need to fall. Cons’ Ozempic forecasts will take time to fall & we will likely need the IRA price in November to force consensus lower. Therefore, we see limited S-T downside to our DKK300 PT. In upcoming research, we will show why the obesity market is materially smaller than expecta...

EUR 4297.50

August 8, 2025 August 8, 2025 1 EN

New Street Research

Novo - Oversize Downgrade - PT Cut to DKK300 (SELL, TP DKK300 [350], 8pgs)

Whilst our downgrade to Sell [here] was predicated on reduced Ozempic sales & significantly below cons. forecasts, the magnitude of the ’25 profit warning has led to a material reset of our forecasts & we are now >30% below cons. EBIT in 2029. We expect the debate to now focus on valuation given we model just 5% 25-30 CAGR sales growth & sema accounts for 60% of 2030 EBIT. Worryingly, our EPS declines in 2027 having cut our sales forecasts by 4-9% & EBIT forecasts by 6%-13%. We are now 27% below 2027 cons. EPS (pre-warning). Given the lacklustre growth of both the diabetes & obesity markets, w...

EUR 4297.50

July 30, 2025 July 30, 2025 1 EN

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Cinclus’ Q2 update focused on balance sheet items and a recap of corporate achievements. The company reported a cash position of SEK589m and operating expenses of SEK80.9m, up from the prior quarter - consistent with expectations given the Phase 3 trial ramp-up. With support from the Zentiva partne

13h / 57m 13h / 57m 1 EN

Oscar Haffen Lamm

Oscar Haffen Lamm

Egetis: Submits pre-NDA meeting, positive recruitment update

Egetis posted a positive US development update on Emcitate with 15 evaluable patients in the US ReTRIACt phase 3 study (vs 12 at previous update) and has submitted a pre-NDA meeting (Type B) request to the FDA, with plans to initiate the submission of the NDA for tiratricol (Emcitate) this year. As

August 18, 2025 August 18, 2025 1 EN

Damien Choplain ... (+2)

Damien Choplain
Oscar Haffen Lamm

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Faron is advancing bexmarilimab (BEX) into a registrational phase 2/3 trial in HR-MDS following a positive EOP2 meeting with the FDA. We view the feedback of broadly positive, as the trial design remains largely unchanged, with a single study expected to support approvals in both frontline and rela

August 18, 2025 August 18, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

NOVO NORDISK - NEUTRAL | DKK330(+20%) Third-quarter figures very much in line with estimates

Novo Nordisk AS: 1 director

Novo - Upgrade to HOLD (PT DKK300, 8pgs)

Novo - Oversize Downgrade - PT Cut to DKK300 (SELL, TP DKK300 [350], 8pgs)

Cinclus Pharma: Q2 driven by BD progress, Phase 3 trial nearing initiation

Egetis: Submits pre-NDA meeting, positive recruitment update

Faron: Positive FDA feedback sends BEX into a registrational phase 2/3 study

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe